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Abstract
Background: The frequency of synonymous codon usage varies widely between organisms. Suboptimal codon content
limits expression of viral, experimental or therapeutic heterologous proteins due to limiting cognate tRNAs. Codon content
is therefore often adjusted to match codon bias of the host organism. Codon content also varies between genes within
individual mammalian species. However, little attention has been paid to the consequences of codon content upon
translation of host proteins.
Methodology/Principal Findings: In comparing the splicing repressor activities of transfected human PTB and its two
tissue-restricted paralogs–nPTB and ROD1–we found that the three proteins were expressed at widely varying levels. nPTB
was expressed at 1–3% the level of PTB despite similar levels of mRNA expression and 74% amino acid identity. The low
nPTB expression was due to the high proportion of codons with A or U at the third codon position, which are suboptimal in
human mRNAs. Optimization of the nPTB codon content, akin to the ‘‘humanization’’ of foreign ORFs, allowed efficient
translation in vivo and in vitro to levels comparable with PTB. We were then able to demonstrate that all three proteins act
as splicing repressors.
Conclusions/Significance: Our results provide a striking illustration of the importance of mRNA codon content in
determining levels of protein expression, even within cells of the natural host species.
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Introduction
With 20 amino acids and a termination signal being encoded by
64 different triplet codons, the genetic code contains redundancy.
Most amino acids are encoded by sets of two or four codons, which
differ in the third, or wobble, position of the codon. Use of
synonymous codons is, however, non-random and in most species
there are clear preferences for particular synonymous codons,
corresponding to the pools of available cognate tRNAs [1].
Consequently heterologous expression of proteins is sometimes
prevented because the open reading frame (ORF) has a codon
content that diverges too much from the codon preference of the
host cells [for example 2,3–9]. The rare AGG and AGA Arg
codons in E. coli are well known to be problematic for expression of
foreign proteins [2]. Another well known example is the Green
Fluorescent Protein from the jellyfish, Aequorea Victoria, which had
to be ‘‘humanized’’ for mammalian expression [10]. Although
individual species show clear codon preferences, it has been
recognized for more than 20 years that individual mammalian
genes can have codon contents that diverge substantially from the
average [11]. The principle source of variation is the G+C vs.A +T
content of codon third positions, which is in turn dictated by large
scale genomic organization into G+C rich and light isochores
[12,13]. The average GC content of human third codon positions
is 59%, but some human genes are enriched in codons ending in A
or T, suggesting that they might face similar barriers to expression
as ectopically expressed proteins from an organism with a distinct
codon preference. We have encountered this phenomenon while
investigating the activities of human Polypyrimidine Tract Binding
protein (PTB, also known as PTBp1 and hnRNP-I) and its tissue
restricted paralogs, nPTB and ROD1.
PTB is a repressive splicing regulator [reviewed in 14,15],
consisting of four RNA Recognition Motif (RRM) domains, each
of which can bind RNA [16]. The optimal RNA binding sites for
PTB consist of motifs such as UCUU or CUCUCU in a pyrimidine
rich context [17]. Such sequences are often associated with
alternatively spliced exons, where they act as splicing silencers (e.g.
[17–20]). PTB exists as two major isoforms referred to as PTB1 and
4 resulting from alternative splicing of exon 9, which leads to the
insertion of an additional 26 amino acids between RRM domains 2
and 3 in PTB4. PTB is expressed in various cell types, but exons that
are repressed by PTB need to be spliced under some circumstances.
There are various ways in which PTB-mediated repression may be
modulated, including the action of antagonistic splicing activators
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paralogs. In addition to the PTB1 and 4 spliced isoforms all
mammals possess at least two PTB paralogs that share 70–80%
amino acid sequence identify with PTB and a conserved overall
domain arrangement, but which are expressed in a restricted
number of cell types. Neuronal PTB (nPTB , also known as PTBp2
and brPTB) is expressed at highest levels in neurons, where PTB
levels are concomitantly decreased. This switch in PTB paralogs is
responsible for switching a subset of neuronal specific alternative
splicing events [24,25]. ROD1 is expressed primarily in hematopoi-
etic cells [26], but as yet there are no reports of its activity as a
splicing regulator. A third paralog, smPTB, has splicing repressor
activity but is present only inrodents [27].We have previously found
that the PTB1 and PTB4 alternatively spliced isoforms have
differential activities upon at least one alternative splicing event
[28,29]. We wished to extend this comparison in experiments
involving transient transfection of cultured cell lines with expression
constructs for the tissue-restricted human paralogs nPTB and
ROD1, as well as the PTB1 and PTB4 spliced isoforms.
To our initial surprise, despite using expression constructs that
provided a common promoter, 59 UTR, N-terminal epitope tag and
39 UTR, and that differed only by the open reading frame (ORF),
the levels of expression of nPTB and ROD1 in a range of cell lines
were only 1–3% those of PTB. We found that expression of nPTB
and ROD1 was limited by their extremely suboptimal codon
content, which was characterized by an enrichment of codons
ending in A or U. By effectively ‘‘humanizing’’ the nPTB ORF we
were able to obtain expression levels similar to PTB, and were then
able to demonstrate that nPTB and ROD1 have splicing repressor
activity similar to PTB. Our data highlights the fact that, in addition
to its familiar effects upon heterologous expression of foreign
proteins, mRNA codon content can have a substantial impact upon
protein expression in an intra-species context.
Materials and Methods
DNA Constructs
Human PTB1, PTB4, nPTB and ROD1 ORF sequences were
used for all constructs. The nPTB* ORF was created synthetically
(see below and Supplementary data). The expression vector was
created by inserting sequence corresponding to the (His)6 and XP
tags of the Invitrogen pcDNA3.1/His C vector (Cat. no. V385-20)
into the Kpn I site of the pCMV-Sport-bgalvector,following removal
of the bgal ORF. PTB1, PTB4, nPTB, ROD1 and nPTB* ORFs
were then cloned into the Kpn I/Sal I sites of this expression vector.
The in vitro translation vector was created by inserting fourteen
nucleotides of the mammalian b-globin 59 UTR into the Eco RI/
Kpn I sites of pGEM3Z (Promega Cat. no. P2151), providing an
adequate distance between the transcription and translation start
sites to allow efficient in vitro translation. PTB1, PTB4, nPTB,
ROD1 and nPTB* ORFs were then cloned into the Kpn I/Sal I
sites of this vector.
The FAS splicing reporter construct was kindly provided by J.
M. Izquierdo and J. Valca ´rcel [30,31]. It contains the human
genomic sequence of the Fas receptor from exon 5 to 7,
inclusively, under the control of the CMV promoter.
The template for transcription of the nuclease protection probe
was created by cloning the sequence common to the expression
vectors, from 100 bp upstream of the transcription start site to just
59 of the PTB ORF, followed by an inverted T7 promoter, into the
Eco RI/Hinc II sites of the pUC19 vector (NEB). The control
probe template was similarly constructed from a 300 bp fragment
starting 100bp upstream of the transcription start site of the
pEGFP-C1 vector.
Sequence Analysis
Codon frequency tables were generated using the codonfre-
quency program within the gcg WISCONSIN PACKAGE [32].
Codon usage and GC content comparisons were carried out
within Microsoft Excel (version X for Mac) spreadsheets. Codon
usage and GC content profiles of an average human ORF were
calculated from the frequency of each codon in 10,000 codons, as
reported in the draft human genome sequence [33]. Sequence
alignments were performed using the ClustalW multisequence
alignment program, available on-line from the EMBL-EBI
(http://www.ebi.ac.uk/clustalw/) [34].
Synthesis of the nPTB* ORF
The design of the codon optimised nPTB* was achieved
through several rounds of analysis and reassignment of synony-
mous codons such that the codon usage and GC content were
more similar to the average human ORF. G+C content at codon
third positions was 64.7% for nPTB*, 86% for PTB, 32% for
nPTB and 59% for the ‘‘average’’ human mRNA (59%). A few
additional substitutions were made to facilitate cloning, but these
did not significantly alter the parameters of interest. An alignment
of the nucleotide sequence of the human nPTB ORF and the
codon optimised nPTB* is shown in Supplementary data.
Oligonucleotides, 70–90 nt in length, overlapping by 20 nt, and
corresponding to the entire length of the nPTB* ORF were
purchased and used in polymerase chain reactions (PCRs) to
generate the full sequence de novo.
Cell Culture Experiments
HEK293, L (mouse fibroblast) and HeLa cells were typically
maintained in 10 cm plates in D-MEM (Gibco BRL) supplemented
with 10% (v/v) FCS and 5% (v/v) L–glutamine at 37uC, 5% CO2.3
to 5610
5 cells were plated in 35 mm diameter wells 24 h prior to
transfection in OptiMEMI medium (Invitrogen) with 3 mLL i p o -
fectAMINE
TMreagent (Invitrogen) and 1 mg DNA (plasmids)
consistinggenerallyof200 ngsplicingreporterornucleaseprotection
control plasmid (pEGFP-C1 from Clontech) and 800 ng expression
plasmid. For control transfections the latter plasmid was substituted
with 800 ng pGEM4Z (Promega). When transfecting less than
800 ng effector plasmid, the remainder of the 800 ng DNA was
made up with pGEM4Z. After 6h at 37uC, 5% CO2, the transfection
medium was replaced with 2 mL usual growth medium. RNA and
protein were harvested 48 h following transfection.
Western Blotting
Cells cultured in 35mm diameter dishes were washed twice with
2 mL PBS and then harvested directly in SDS loading buffer.
Equivalent volumes were loaded on 15% SDS-PAGE gels.
Standard immunoblotting procedures were followed using the
anti-XPress mouse monoclonal antibody (Invitrogen, Cat. no.
R910-25) at 1/1000 and the anti-ERK-1 (K2) rabbit polyclonal
antibody (Santa Cruz Biotechnology Inc., Cat. no. sc-94) at 1/
15,000. Membrane stripping for re-probing was carried out with
the Re-Blot Plus Strong Antibody Stripping Solution (Chemicon
International Inc., Cat. no. 2504).
Harvesting RNA from Cultured Cells
For analysis of splicing products, cells cultured in 35 mm
diameter dishes were washed twice with 2 mL PBS, then total
mRNA was harvested using either TRIReagent (SIGMA), or
PURESCRIPTH solutions (Gentra Systems) following manufac-
turer’s instructions. Cytoplasmic RNA was harvested for nuclease
protection assays 48 h following transfection of cells. Cells were
‘‘Humanizing’’ a Human ORF
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NaCl, 5 mM MgCl2, 2% NP-40, 50 mM Tris, pH 8.3, 10 mM
vanadyl ribonucleoside complex for 2 min on ice. Nuclear
fractions were pelleted by centrifugation and discarded. The
cytoplasmic supernatant was extracted twice with phenol/CHCl3
(1:1) at 65uC, then with CHCl3 alone and finally precipitated with
NaOAc in ethanol. Any genomic DNA carried over was digested
with RQ1 DNase (Promega) for 30 min at 37uC.
Analysis of FAS Reporter Splicing Products
cDNA was synthesized from 2mg RNA using avian myeloblas-
tosis virus (AMV) reverse transcriptase (RT, Promega) in its
commercially supplied buffer with 40 pmol RT primer (59TTG
TGC CCA TTA ACA TCA AGC TTG CAT CGA ATC AGT
AG 39). PCR amplification used 1/20
th of the RT reaction as
template and 250ng each of the following primers: 59 GTC GAC
GAC ACT TGC TCA AC 39 and 59 TTG TGC CCA TTA ACA
TC 39. RT-PCR products were analysed on 2% agarose gels. A
digital image of the gel was obtained using a SynGene (www.
syngene.com) apparatus and the SynGene GeneSnap software
(version 4.00.00). Individual band intensities were quantitated
using the SynGene GeneTools software (version 3.00.13). The
‘‘peak definition by integration’’ method was used for quantitation
with the ‘‘rolling disk’’ method of background correction. These
values were used to calculate the proportion of each product
within a single RT-PCR reaction.
Nuclease Protection Assays
Probes were transcribed with T7 RNA polymerase (prepared in-
house) from the EcoR I linearised DNA templates described above,
incorporating [a
32P]UTP (GE Biotech) throughout. DNA tem-
plate was destroyed by RQ1 DNase digestion and the probes
purified over a polyacrylamide gel. Nuclease protection assays of
cytoplasmic RNA harvested from transfected cultured cells were
conducted using the RPAIII kit (Ambion, Cat. no. 1415) as per the
manufacturer’s instructions, and run on denaturing polyacryl-
amide gels. Results were quantified with a PhosphorImager and
ImageQuaNT software (Molecular Dynamics).
In Vitro Transcription and Translation
Capped mRNAs for in vitro translation were transcribed with T7
RNA polymerase from DNA templates linearized with HindI I I
(PTB1, PTB4, ROD1 and nPTB*) or Acc I (nPTB), incorporating
trace amounts of [a
32P]UTP throughout, and the RNAs were
isolated and quantitated as described [35]. Translation reactions
incorporating [
35S]methionine were carried out in 50–70% (by vol.)
nuclease-treated rabbit reticulocyte lysate (Promega), as previously
described [36,37]. Standard translation conditions included 10 mM
creatine phosphate, 50 mgm l
21 creatine kinase, 4 mM 2-amino-
purine, 100 mM KCl, 0.5 mM MgCl2, 0.1 mM of each amino acid
except methionine, and 500 mCi ml
21 [
35S]-methionine. Where
indicated the lysate was supplemented with calf liver tRNA (Sigma)
to a final concentration of 60 mgm l
21. In some experiments edeine
was added to 1 mM to inhibit further rounds of translation initiation.
Translation products were separated on a 15% polyacrlyamide gel
and visualised by autoradiography with Hyperfilm bmax (GE) or
Biomax film (Kodak). Quantitation was carried out by densitometry
of the autoradiograms using Phoretix software.
Results
Differential expression of PTB paralogs
In order to achieve equivalent levels of expression, the open
reading frames (ORFs) for human PTB1, PTB4, nPTB and
ROD1 were cloned into an expression vector that provided a
common CMV promoter, 59 and 39 untranslated sequences and
an N-terminal Xpress epitope tag (Fig 1A). The constructs were
transiently co-transfected into a range of mammalian cell lines
along with a GFP expression vector as a transfection control.
Unexpectedly, western blotting for the Xpress epitope tag showed
much lower expression of nPTB and ROD1 than of PTB1 and
PTB4 in all cell lines tested (Fig. 1B,E,G). Reprobing the blots with
anti-ERK antibody demonstrated the equivalence of protein
loading between samples. Comparison with serial dilutions of total
protein lysates from PTB1 transfections indicated that nPTB
protein expression levels were 1–3% those of PTB1 in 293 and
HeLa cells (Fig 1C,H). The difference in protein expression was
evident at various time-points after transfection, arguing against
the possibility that the paralogs might be expressed equally but fail
to accumulate due to lower stability (data not shown). The
possibility that overexpression of nPTB and ROD1 might be toxic
to cells was ruled out by cotransfecting PTB, nPTB and ROD1
with a b-galactosidase reporter; no differences in numbers of
stained cells were observed (data not shown).
RNA levels were analyzed in parallel by nuclease protection
analysis (Fig 1 D,F,I) using a test probe (T) that protects a region
corresponding to the Xpress tag present in all transfected
constructs, and a control probe (C) that protects a region of the
cotransfected GFP, providing an internal control for all experi-
mental samples. Levels of nPTB RNA were comparable to those of
PTB1 in L cells and reduced to ,40% in HeLa cells and to 20%
in 293 cells. The relatively modest differences in RNA levels
cannot explain the much larger differences in PTB, ROD1 and
nPTB protein expression. Indeed, it is likely that the reduced RNA
levels may be a downstream consequence of translational stalling
(see below). The large variation in protein expression is especially
surprising, considering that the amino acid sequences of the four
proteins are .74% identical.
Suboptimal codon contents limit nPTB and ROD1
expression
The expression constructs were identical with the single
exception of the ORFs of the proteins being expressed. We
analyzed the sequences of the PTB, nPTB and ROD1 ORFs
seeking clues to the observed differential expression. PTB
expression is negatively autoregulated at the level of splicing
[38]. We, therefore, initially searched for sequence motifs
corresponding to optimal binding sites for PTB, with the rationale
that negative feedback loops operating at the translational level
might prevent overexpression of nPTB and ROD1. However, we
found no differences in the occurrence of PTB binding sites, or of
motifs associated with RNA or protein stability. The one striking
difference between nPTB and ROD1 compared to PTB lay in the
G+C versus A+T composition of their ORFs (Figure 2). Both
nPTB and ROD1 have a lower G+C composition (41.2 and
43.9% respectively) than PTB (60.5%). Moreover, analysis by
codon position revealed that this variation in G+C richness was
entirely confined to the third codon position (Figure 2B; PTB
86%, ROD1, 35%, nPTB 32%), whereas the first and second
codon positions had nearly identical nucleotide composition (not
shown). This confinement of the variation to the third codon
position is consistent with the high degree of amino acid sequence
identity between the three proteins. Consequently, nPTB and
ROD1 have a very distinctive codon composition, with a high
frequency of codons ending in A or T, while PTB has a much
higher proportion of codons ending in G or C. Strikingly, codon
bias in the human genome shows an overall preference for G or C
in the third codon position (,59%) [33]. These observations
‘‘Humanizing’’ a Human ORF
PLoS ONE | www.plosone.org 3 2008 | Volume 3 | Issue 3 | e1801Figure 1. Differential overexpression of PTB, nPTB and ROD1. A) Expression constructs featured a CMV promoter, common 59 and 39 UTRs
and an N-terminal Xpress epitope tag. Open reading frames (ORF) for PTB and its paralogs were the only variable between constructs. nPTB* is the
codon-optimized nPTB expression construct described in the text. B) Western blots of 293 cells transfected with the indicated constructs, probed with
anti-Xpress (XP, upper panel) or anti-ERK antibodies. Positions of size markers (kDa) are indicated to the right. C) Western blot comparing the anti-
Xpress signal obtained from a dilution series of protein from PTB1 transfected 293 cells (1.0, 0.5, 0.25, 0.062, 0.031 and 0.01 equivalents) with 1.5
equivalents from an nPTB transfection (left hand lane). D) Nuclease protection assay of cytoplasmic RNA harvested from 293 cells transfected with the
constructs indicated above. 4Z is a mock transfection (pGEM4Z). ‘‘T’’ is the test probe, corresponding to the Xpress probe region of the expression
construct, while ‘‘C’’ is a control probe detecting the cotransfected GFP construct. Positions of size markers (nt) are indicated to the left. E) Western
blots of L cells transfected with the indicated constructs, probed with anti-Xpress (XP, upper panel) or anti-ERK antibodies. 4Z is a mock transfection
(pGEM4Z). F) Nuclease protection of cytoplasmic RNA from L cells. Details as in ‘‘D’’. G) Western blots of HeLa cells transfected with the indicated
constructs, probed with anti-Xpress (XP, upper panel) or anti-ERK antibodies. H) Western blot comparing the anti-Xpress signal obtained from a
dilution series of protein from PTB1 transfected HeLa cells (1.0, 0.5, 0.25, 0.062, 0.031 and 0.01 equivalents) with 1.5 equivalents from an nPTB
transfection (left hand lane). I) Nuclease protection of cytoplasmic RNA from HeLa cells. Details as in ‘‘D’’.
doi:10.1371/journal.pone.0001801.g001
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nPTB in transfected cells might be due to the enrichment in
ROD1 and nPTB of suboptimal codons ending in A and T, which
might limit the efficiency with which they are translated.
As an initial test of this hypothesis we analysed a 1-hour time-
course of in vitro translation of PTB1, PTB4, nPTB and ROD1
mRNA in rabbit reticulocyte lysate in the presence or absence of
supplementary tRNAs (Fig. 3A,B). Supplementary tRNA is
routinely added to reticulocyte lysate with the express purpose of
preventing tRNA availability from limiting translation efficiency
[37]. ROD1 and nPTB showed a much higher level of induction
of translation upon tRNA supplementation than PTB (Fig. 3B)
consistent with the hypothesis that their translation is otherwise
limited by the availability of cognate tRNAs. Over most of the
time-points the levels of induction of nPTB and ROD1 were
similar, although at the 20 minute time-point, nPTB translation
was activated to a higher degree than ROD1 (Fig 3B). As a further
test of this hypothesis, we analysed in vitro translation in the
presence or absence of supplementary tRNA at a fixed time-point
(1 hour) with increasing quantities of mRNAs (Fig 4A). Transla-
tional yield was expected initially to increase with mRNA
concentration. However, at higher mRNA concentrations some
tRNAs might become limiting, leading to a decreased yield of full-
length protein in the non-tRNA-supplemented samples. We would
also expect to observe the accompanying appearance of truncated
protein products associated with ribosomal stalling at codons for
which the cognate tRNA is unavailable. Consistent with these
predictions, in the absence of tRNA supplementation both nPTB
and ROD1 showed a biphasic response to mRNA concentration.
An initial increase in yield of full-length product was followed by a
decrease, with a concomitant appearance of a number of
truncated products (Fig 4A lanes 16–20, 26–30, truncated
products indicated by white arrowheads adjacent to lanes 20
and 30). A possible alternative explanation for the appearance of
truncated nPTB products is endonuclease cleavage of the nPTB
mRNA. However, degradation would be expected to affect a
progressively smaller fraction of total mRNA with increasing
mRNA concentration. In contrast to nPTB and ROD1, PTB1
translation increased with mRNA concentration and no decrease
in yield of full-length product was observed. This is consistent with
a higher abundance of the tRNAs required for translation of
PTB1. Notably, upon tRNA supplementation, translation of nPTB
and ROD1 no longer showed a biphasic response to mRNA
titration (lanes 11–15, 21–25).
In order to confirm that the truncated nPTB products observed
under conditions of limiting tRNA were due to ribosomal stalling at
codons for which the cognate tRNA was limiting, we carried out
chase experiments. Truncated products were initially allowed to
accumulate, followed by the addition of supplementary tRNA and
the translation initiation inhibitor edeine (Fig 4B). Translation for 30
or 60 minutes in the absence of tRNA supplementation showed the
expected accumulation of truncated nPTB products (Fig 4B, lanes
1,2). Addition of edeine at 30 min had no effect upon the profile of
products at 60 min (lane 3). However, addition of both tRNA and
edeine at 30 min led to dramatically increased production of full
length nPTB at 60 min (lanes 4 and 5, duplicate samples). Thus, the
truncated products formed under conditions of limiting tRNA (lanes
2,3) can be chased into full length products by the addition of tRNA
(lanes 4,5). This is consistent with ribosomal stalling at codons for
which the cognate tRNA is particularly scarce. This experiment
demonstrates that there is no significant ‘‘drop-off’’ of stalled
ribosomes. It also rules out the possibility that the truncated proteins
are produced from nPTB mRNAs that have been preferentially
targeted by endonucleolytic ribonucleases.
‘‘Humanizing’’ a human ORF
The preceding experiments suggested that lack of expression of
human nPTB and ROD1 in transiently transfected human cell
lines was related to their suboptimal codon content and the
attendant scarcity of required tRNAs. Limitation of expression of
foreign proteins in cells of another organism has been observed
frequently, and has commonly been circumvented by adapting
their codon content to more closely resemble the host organism
codon bias [3–10]. We, therefore, decided to apply the same
principle and constructed a human codon-optimized nPTB ORF
(referred to as nPTB*) with 211 silent mutations, encoding an
identical nPTB amino acid sequence (Fig 5). The complete nPTB*
ORF, and the third codon position in particular, showed a
nucleotide composition more similar to that of PTB. The third
codon position of nPTB* (64.7% G+C) was closer to the human
‘‘average’’ human mRNA (59%) than either PTB (86%) or nPTB
(32%). The codon-optimized nPTB* showed no evidence of tRNA
limitation in the in vitro mRNA titration (Fig 4A, lanes 31–40).
Moreover in all cell types tested, transient transfection of the
nPTB* construct resulted in the production of nPTB protein at
levels comparable to that of PTB (Fig 1B,E,G). The high level of
protein expression from the nPTB* ORF most likely arises from its
improved human codon usage profile. An alternative possibility is
that the large number of base changes introduced in the
construction of nPTB* might have altered secondary structures
in the mRNA. However, the vast majority of changes were U to C
or A to G, which would be expected to increase the overall stability
of secondary structure. Indeed the maximum stabilities of
structures predicted by Mfold were 2359.7 kcal mol
21 for nPTB,
but 2426.4 kcal mol
21 for nPTB*. The only commonly known
influence of higher stability secondary structures is decreased
Figure 2. Nucleotide content of human PTB and paralog open
reading frames and third codon positions. Histograms show the
frequency (%) of the four bases in PTB1, nPTB, ROD1 and the codon-
optimized nPTB* for (A) the complete ORFs, and (B) the third codon
position.
doi:10.1371/journal.pone.0001801.g002
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explanation for the improved translational yield is unlikely. The
simplest explanation consistent with all the data is that the higher
expression of nPTB* relative to nPTB is related to its optimized
codon content. Taken together, the transfection and in vitro
translation data (Figs 1,3,4) suggest that poor codon composition
restricts nPTB protein expression, even though its mRNA may be
present at high levels.
PTB Paralogs are Splicing Repressors
Having overcome the expression limitations of nPTB we were
now able to compare its splicing repressor activity with PTB. FAS
exon 6 has been shown to respond to overexpressed PTB via a
single exon splicing silencer [31]. When transfected into L cells the
construct RNA is spliced with predominant inclusion of exon 6
(Fig 6B, lane 5). Overexpression of PTB1 or PTB4 produce a shift
towards exon 6 skipping (lanes 1,2). When expressed at levels
comparable to PTB1 and PTB4, nPTB, expressed from the
nPTB* construct, promoted exon skipping to the same extent as
PTB (Fig 6B, lane 3). The original nPTB expression plasmid never
had any effects upon cotransfected splicing reporters (data not
shown), presumably due to the lack of protein expression (Fig 1,
6A). In this set of experiments ROD1 was also expressed at
comparable levels (Fig 6A) and also promoted FAS exon 6 skipping
to a similar level as PTB and nPTB (Fig 6B, lane 4). These data
demonstrate that both human tissue-restricted paralogs of PTB
have splicing repressor activity.
Discussion
It has been known for over 20 years that the codon contents of
genes varies widely within individual vertebrate species, with the
variation being determined by the G+C vs.A +T content of codon
wobble positions [11]. Nevertheless, it has also been clear that
individual species have preferences for particular codons, and that
variation in codon preferences between species frequently acts as a
barrier to experimental over-expression of proteins in host cells of
a different species [2–9]. As a consequence, many investigators
have resorted to ‘‘humanizing’’ the codon content of non-human
cDNAs in order to achieve expression in human cells. Despite the
recognized variability in codon content of human genes [11], little
attention has been focused upon the possibility that expression of
Figure 3. Translation in vitro of PTB and paralogs. A) Translation was carried out in rabbit reticulocyte lysate pre-treated with micrococcal
nuclease [37] in the presence or absence of additional calf liver tRNA (60 mgm l
21) over a time-course of 12, 20, 30, 45 and 60 min, and with
10 mgm l
21 of mRNA. Sizes (kDa) of the markers in the left-most lane are indicated to the left of the autoradiogram. B). The effect of tRNA
supplementation on relative protein translation in ‘‘A’’ is depicted schematically as the ratio of full-length product produced in the presence and
absence of tRNA supplementation.
doi:10.1371/journal.pone.0001801.g003
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content of their mRNAs. On the contrary, there appears to have
been a widespread tacit assumption that even though some human
ORFs may have an unusually low G+C content in the wobble
positions, the deviation from average is not so extreme as to
restrict protein expression due to limiting cognate tRNA
availability. Certainly, there seem to have been remarkably few
attempts to improve the expression of a mammalian protein in
mammalian cells by optimizing wobble positions (reviewed in
[41]). In one of the few exceptions, overexpression of human
erythropoietin in mammalian cells was shown to be influenced by
engineering to contain human (high G+C) or yeast (high A+T)
optimized codons, although expression levels differed by only 2.5-
fold [42]. Our data demonstrate that inter-gene codon bias can
have substantially greater effects upon protein expression within
cells of the same organism (Fig 1C,H). Expression levels of the
human nPTB protein were 30–100 fold less than those of PTB, or
of the codon optimized nPTB* in transfected human cells (Fig 1).
RNA levels in the same cells were similar to those of PTB, or only
slightly lower, and were insufficient to account for the much larger
differences in protein levels. Indeed, it seems plausible that RNA
levels may have been slightly depressed as a consequence of
translational effects. In vitro translation of nPTB showed evidence for
translational stalling at discrete positions (Fig 4). Translational
stalling has been associated with endonucleolytic mRNA cleavage in
vivo [43], so the lower amounts of nPTB and ROD1 mRNA
compared to PTB in 293 and HeLa cells (Fig 1, C,I) could have
resulted from inefficient translation elongation. Our conclusions
Figure 4. Ribosomal stalling on nPTB mRNA. A) Translation was carried out for 1 hr in the presence and absence of supplementary tRNA,
titrating the amount of template mRNA (2.5, 5, 10, 20, 40 mgm l
21). Lanes M, protein size markers (sizes in kDa indicated to the left). For clarity only
the lane numbers for the lowest and highest concentration of each mRNA are indicated below. Positions of truncated nPTB and ROD1 products are
indicated by white arrowheads to the right of lanes 20 and 30. B) Translation of nPTB mRNA (80 mgm l
21) was carried out for 60 min except for lane 1,
which was stopped at 30 min. Edeine (1 mM) was added at 30 min (lane 3,4,5) or at 0 min (lane 7). Calf liver tRNA (60 mgm l
21) was added at 30 min
(lane 4 and 5) or at 0 min (lane 6), as indicated. Lanes 4 and 5 are identical replicates. Lanes ‘‘M’’, molecular size makers. Lanes M, protein size markers
(sizes in kDa indicated to the left). Truncated products accumulated in the absence of supplementary tRNA could be chased into full length products
by addition of tRNA (compare lane 3 with 4 and 5).
doi:10.1371/journal.pone.0001801.g004
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G+C composition upon gene expression [41]. In that study, protein
and mRNA levels were seen to vary widely with GC content.
Translation-level effects were discounted on the basis of comparable
in vitro translation time-courses of two mRNAs that had 93% and
46% G+C content at third codon positions (compared to 89% and
32% for PTB and nPTB). However, the standard commercially
available in vitro translation system includes excess tRNAs which can
disguise the effects of codon composition upon translation (Fig 3).
While many of the cases reported in [41] show large changes in
mRNA levels in response to GC content, our observations and
others [44,45] argue that in some cases large translational effects are
dominant over relatively minor RNA level effects.
On the basis of established molecular principles our observa-
tions are not in themselves surprising, but the magnitude of the
effect is remarkable. They suggest that codon content should be an
important practical consideration when problems are encountered
with protein expression in cell culture, even when the protein and
the cells are con-specific. Re-building the ORF, as we have done
for nPTB, is a serious undertaking, but it can facilitate lines of
investigation that would otherwise have been precluded.
The most plausible explanation for the effect of codon
composition upon protein levels is scarcity of the required cognate
tRNAs. Various examples of eukaryotic cells with skewed tRNA
populations matching the amino acid composition of proteins that
are expressed at particularly high levels have been reported [46–
49]. Therefore, the converse situation is feasible—that cognate
tRNA availability might limit expression of an ORF that is
enriched in usually rare codons. It is not readily apparent whether
there is a specific subset of rare codons that are responsible for the
poor translation of nPTB. The in vitro translation experiments
(Fig 4) showed evidence for translational stalling at up to 14
specific positions. The sizes of these truncated products showed no
obvious correlation with clusters of a particular type of rare codon,
and it seems likely that codons with U in the wobble positions and
those with A were both contributing to the inefficient expression,
even if not to the same extent. Systematic identification of
problematic codons would probably best be approached by
Figure 5. Sequence of nPTB and nPTB* open reading frames. The amino acid sequence is shown on the top line, the human nPTB nucleotide
sequence is shown on the second line and the wobble position mutations to create the codon-optimized nPTB* are shown on the third line. The Asp
718 and Sal I sites used for cloning are underlined.
doi:10.1371/journal.pone.0001801.g005
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location within an otherwise ‘‘normal’’ human ORF, rather than
starting with nPTB in which so many codons appear to be
suboptimal.
We overcame the translational impediments of the native human
nPTBORF bydenovooligonucleotidebased constructionofanentire
synonymous nPTB* ORF. In order to maximize the chances of
success, we did not try to identify particular problem codons, but
adjusted the entire ORF so that it was closer in composition to the
human average. Of the 211 silent mutations 47% were U to C, 22%
A to G, 17% A to C and 13% U to G. Thus, 60% of the mutations
removed U from the wobbleposition and theremainder removed an
A.ForeverysynonymousNNA/Gcodonpair,nPTB showsahigher
proportion of codons ending in A compared to both PTB and the
human average. The highest enrichment of NNA over NNG codons
innPTB compared with the human average,isinthe codons for Leu
CTA/G (4.1 fold), Arg CGA/G (2.8 fold), Val GTA/G (2.3 fold)
and Gln CAA/G (1.9 fold). For the decoding of NNG/A codons, a
tRNA with C in the wobble positions reads only NNG, whereas a
tRNAwith a modified U in this position decodes NNA and may also
becapableofreading NNG,depending uponthe exactmodification.
Thus, there could well be a higher concentration of tRNAs cognate
for NNG than for NNA, and this concentration difference could be
the complete explanation of the beneficial effect of the A to G
mutations. By contrast, all tRNAs cognate for NNC can also read
NNU [33,50], irrespective of whether the tRNA wobble base is G or
I.Therefore, any improvement intranslation resulting fromthe 47%
UtoCmutationscannotbeduetodifferentialtRNAconcentrations,
but mustbe due to a greater efficacy of the tRNA inreading NNC as
opposed to NNU. In fact, it as been shown that bacterial aminoacyl-
tRNAs with G at the first antcodon position bind more rapidly to
ribosomes programmed with codons ending in C than in U [51,52].
Our experiments were based upon overexpression by transient
transfection, and in vitro translation. The extent to which codon
bias influences gene expression in vivo remains an open question.
One possibility is that codon content presents a uniform restriction
to nPTB expression across various cell types. Alternatively, cell-
type specific variations in tRNA availability might lead to
differential translatability, possibly in neurons. The possibility that
variations in codon usage might be associated with expression in
different human tissues has been suggested [53]. Indeed,
papillomavirus L1 protein is translated in differentiated but not
undifferentiated keratinocytes despite similar levels of mRNA, and
this has been suggested to be explained by differential tRNA
populations [45]. However, only 2.3% of synonymous codon
variability can be accounted for by tissue-specific expression; the
major influence upon codon variability is genome isochore
structure [1,54]. Introns within the nPTB and ROD1 genes have
a much higher A+T content than PTB introns, consistent with the
location of these genes in G+C light isochores. Indeed, this
genomic arrangement is conserved in the murine nPTB and
ROD1 orthologs, which show very similar suboptimal codon
compositions. The unusual codon content that is imposed upon
nPTB by its location in a low G+C isochore could act as a uniform
constraint upon translation in various cell types. An alternative,
tantalizing, possibility is that cell-specific tRNA populations may
modulate the translatability of nPTB. Investigating whether cell-
type specific pools of tRNA modulate nPTB translation would first
require the identification of cell line(s) that show an altered
hierarchy expression from transfected PTB, nPTB and ROD1
constructs. However, all cell lines that we tested showed the same
hierarchy of expression (Fig 1). It is possible that this line of
investigation could be pursued in a suitable transfectable neuronal
cell line, which might show enhanced nPTB translation. In the
absence of transfection of constructs that differ only in the PTB/
nPTB ORFs it would be difficult to disentangle nPTB regulation
by tRNA availability from the numerous other levels at which its
expression is regulated (see below).
Having engineered the nPTB* ORF, we were able to
demonstrate by cotransfection that nPTB has similar repressor
activity as PTB upon FAS exon 6. In vitro assays with an a-
tropomyosin pre-mRNA substrate have also indicated that nPTB
has repressor activity similar to PTB [29]. In addition, the nPTB*
construct has subsequently been used to complement the effects of
Figure 6. Splicing repressor activity of nPTB and ROD1. A splicing reporter comprising FAS exons 5-6-7 [31] was cotransfected with expression
constructs for PTB1, PTB4, nPTB* and ROD1 into L cells. PGEM4Z was used in the negative control. FAS exon 6 contains a single PTB binding site that
mediates exon skipping [31]. A) Western blot probed with anti-Xpress (top) and anti-ERK (lower panel) antibodies. Size markers (kDa) are indicated to
the left. Comparable levels of expression were obtained for PTB, ROD1 and nPTB from the codon-optimized nPTB* construct, but not from the
original nPTB construct. B) RT-PCR analysis of FAS construct splicing. Products were separated by agarose gel electrophoresis. Lane M, size markers
(bp), indicated to the left. Lanes 1-5, PTB1, PTB4, nPTB*, ROD1 and pGEM4Z respectively. Numbers immediately below each lane indicate the
percentage of spliced product that includes exon 6. Both nPTB* and ROD1 were able to induce similar levels of exon skipping as PTB. Note that nPTB
was not included in this panel because the protein is not adequately expressed (panel A).
doi:10.1371/journal.pone.0001801.g006
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reporter constructs [55]. Therefore despite the fact that nPTB is
less repressive than PTB upon the SRC N1 exon [56], for other
splicing events it has repressor activity similar to PTB. This is
consistent with recent findings that replacement of PTB by nPTB
in neurons has differential effects on large numbers of neuronally
regulated exons [24,25]. While the role of nPTB in the regulation
of neuronal alternative splicing has been investigated, to our
knowledge this is the first demonstration that ROD1 also acts as a
splicing repressor. The codon composition of ROD1 mRNA is
slightly less extreme than that of nPTB, and ROD1 expression was
more variable between experiments (Figs 1,6). While nPTB
expression was uniformly low in all experiments, in some cases
we obtained high expression levels of ROD1 and we were able to
test its splicing regulatory activity (Fig 6). We therefore did not
construct a codon-optimized ROD1 vector. However, alternative
splicing is a major contributor to generating protein isoform
diversity in the immune system [57], and ROD1 may contribute to
this process, perhaps having variable activity upon a subset of
hematopoietic alternative splicing events. A reliable codon-
optimized ROD1 construct might prove useful in the future
investigation of its functions.
Expression of nPTB protein is controlled at a number of post-
transcriptional levels. Even though it is transcribed in cells other
than neurons, a PTB-induced exon skipping event leads to
Nonsense Mediated Decay of the bulk of nPTB mRNA in non-
neuronal cells [24,25]. In addition, it is subject to miRNA
mediated translational repression [58]. Both these mechanisms
restrict nPTB protein to a narrower range of cell types than nPTB
mRNA. Translational control by codon bias, as described here,
adds a further layer to this complex arrangement of post-
transcriptional control.
As a final comment, it is perhaps worth noting that our
references to the ‘‘suboptimal’’ codon content of nPTB mRNA are
very much from the perspective of the experimental investigator
trying to overexpress a protein. While unusual, the codon
composition of both nPTB and ROD1 may, in fact, be optimized
for appropriate regulated protein expression.
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